Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

Provided By PR Newswire

Last update: Sep 16, 2025

SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Oncolytics Biotech^® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced updates on enrollment progress, U.S. site expansion, and expected data readouts from the ongoing GOBLET trial evaluating pelareorep in gastrointestinal cancers. The study is supported in part by a grant from the Pancreatic Cancer Action Network (PanCAN).